Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 369, Issue 1-2, Pages 136-143Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2008.10.016
Keywords
Drug delivery; Nanoparticles; Nifedipine; Dry powder aerosol
Categories
Funding
- NIH [R03 AR054035, P20 RRO16443, T32 GM08359-11]
- NSF [CHE 0719464]
- Direct For Mathematical & Physical Scien [1265397] Funding Source: National Science Foundation
- Division Of Chemistry [1265397] Funding Source: National Science Foundation
Ask authors/readers for more resources
Efficient administration of drugs represents a leading challenge in pulmonary medicine. Dry powder aerosols are of great interest compared to traditional aerosolized liquid formulations in that they may offer improved stability, ease of administration, and simple device design. Particles 1-5 mu m in size typically facilitate lung deposition. Nanoparticles may be exhaled as a result of their small size; however, they are desired to enhance the dissolution rate of poorly soluble drugs. Nanoparticles of the hypertension drug nifedipine were co-precipitated with stearic acid to form a colloid exhibiting negative surface charge. Nifedipine nanoparticle colloids were destabilized by using sodium chloride to disrupt the electrostatic repulsion between particles as a means to achieve the agglomerated nanoparticles of a controlled size. The aerodynamic performance of agglomerated nanoparticles was determined by cascade impaction. The powders were found to be well suited for pulmonary delivery. In addition, nanoparticle agglomerates revealed enhanced dissolution of the drug species suggesting the value of this formulation approach for poorly water-soluble pulmonary medicines. Ultimately, nifedipine powders are envisioned as an approach to treat pulmonary hypertension. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available